x
Filter:
Filters applied
- Opioids
- CNSRemove CNS filter
- DREADDRemove DREADD filter
Keyword
- AAV1
- adeno-associated virus1
- Cav1
- CCD1
- central nervous system1
- clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 91
- conventional drug discovery1
- CRISPR/Cas91
- designer receptors activated by designer drugs1
- dorsal root ganglion1
- DRG1
- ED1
- GABA1
- HSV1
- IL-101
- IT1
- Kv1
- N-methyl-d-aspartate1
- Nav1
- NK11
- NMDA1
- TRP1
- TRPV11
Opioids
1 Results
- Symposium on pain medicine
Future Directions in Pain Management: Integrating Anatomically Selective Delivery Techniques With Novel Molecularly Selective Agents
Mayo Clinic ProceedingsVol. 91Issue 4p522–533Published in issue: April, 2016- Josef Pleticha
- Timothy P. Maus
- Andreas S. Beutler
Cited in Scopus: 8Treatment for chronic, locoregional pain ranks among the most prevalent unmet medical needs. The failure of systemic analgesic drugs, such as opioids, is often due to their off-target toxicity, development of tolerance, and abuse potential. Interventional pain procedures provide target specificity but lack pharmacologically selective agents with long-term efficacy. Gene therapy vectors are a new tool for the development of molecularly selective pain therapies, which have already been proved to provide durable analgesia in preclinical models.
